70474-53-2

Basic information

• Product Name: N-(3',4'-dimethoxy-β-phenethyl)-3-thienylacetamide
• CAS NO: 70474-53-2
• Molecular Weight: 305.398
• Mol File: 70474-53-2.mol
• Article Data: 4

Chemical Properties

• CAS DataBase Reference: N-(3',4'-dimethoxy-β-phenethyl)-3-thienylacetamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3',4'-dimethoxy-β-phenethyl)-3-thienylacetamide(70474-53-2)
• EPA Substance Registry System: N-(3',4'-dimethoxy-β-phenethyl)-3-thienylacetamide(70474-53-2)

Safety Data

• Hazardous Substances Data: 70474-53-2(Hazardous Substances Data)

Upstream product

• 6964-21-2 thiophen-3-yl-acetic acid 
• 120-20-7 2-(3,4-dimethoxyphenyl)-ethylamine 

Relevant articles and documents

Design, synthesis, and biological evaluation of tetrahydroisoquinolines derivatives as novel, selective PDE4 inhibitors for antipsoriasis treatment

Psoriasis is a kind of chronic inflammatory skin disorder, while the long-term use of conventional therapies for this disease are limited by severe adverse effects. Novel small molecules associated with new therapeutic mechanisms are greatly needed. It is known that phosphodiesterase 4 (PDE4) plays a central role in regulating inflammatory responses through hydrolyzing intracellular cyclic adenosine monophosphate (cAMP), making PDE4 to be an important target for the treatment of inflammatory diseases (e.g. psoriasis). In our previous work, we identified a series of novel PDE4 inhibitors with a tetrahydroisoquinoline scaffold through structure-based drug design, among which compound 1 showed moderate inhibition activity against PDE4. In this study, a series of novel tetrahydroisoquinoline derivatives were developed based on the crystal structure of PDE4D in complex with compound 1. Anti-inflammatory effects of these compounds were evaluated, and compound 36, with high safety, permeability and selectivity, exhibited significant inhibitory potency against the enzymatic activity of PDE4D and the TNF-α release from the LPS-stimulated RAW 264.7 and hPBMCs. Moreover, an in vivo study demonstrated that a topical administration of 36 achieved more significant efficacy than calcipotriol to improve the features of psoriasis-like skin inflammation. Overall, our study provides a basis for further development of tetrahydroisoquinoline-based PDE4 inhibitors against psoriasis.

Studies on Heterocyclic Compounds: Part II - Synthesis of Thiophene Isosters of Aporphine Alkaloids

Photosynthesis of N-carbethoxy-1,2-dimethoxy-4,5,6-trihydrobenzothienoquinoline (6a) and the 1-benzyloxy compound (6b), which are D-ring thiophene isosters of N-carbethoxy aporphine derivatives, is described.The synthetic sequence involves Bisc